Cleveland BioLabs has granted an exclusive China license for Protectan CBLB612, an investigational cancer drug, to Zhejiang Hisun Pharmaceutical Co. Ltd. In animal studies, the drug has been shown to stimulate hematopoietic stem cell proliferation and mobilization. Cleveland BioLabs says the drug shows promise as a treatment for the negative side-effects of chemotherapy. More details...

Stock Symbols: (NSDQ: CBLI) (SHSE: 600267)